BASEL (dpa-AFX) - Novartis (NVS) announced 14-month results from the pivotal JULIET clinical trial showing ongoing durable responses are achievable with Kymriah (tisagenlecleucel) when administere...
More From BioPortfolio on "Novartis JULIET Trial Of Kymriah Shows More Than 1-Yr Durability Of Responses"